SEC Form 4 · accession 0000899243-18-024905
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel C. Martin
Officer — Chief Commercial Officer
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 18, 2018 | A | 20,000 | $0.00 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $36.10 | Sep 18, 2018 | A | 90,000 | A | — | Sep 17, 2028 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1The reporting person was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal annual installments over two (2) years beginning on September 18, 2018. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- F2This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the shares shall vest on September 18, 2019 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to continued service through such dates.